Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- AbbVie Files New Dosage Forms for Skyrizi in Japan
September 29, 2020
- Approval Now in Hand, CureApp Looks at Collaborations with Drug Makers to Push Therapeutic Apps
September 29, 2020
- Sawai, Susmed Pair Up in Digital Healthcare Field
September 28, 2020
- Shionogi Delays Saliva-Based COVID-19 Test Launch to December
September 25, 2020
- Astellas, Univ. of Pittsburgh Ink Research Pact for Dry AMD
September 25, 2020
- Taiho Hooks Up with MD Anderson on Refractory Cancers
September 25, 2020
- Sawai Can Set Itself Apart from Competitors in Post-80% Generic Era through Development Strategy: President
September 25, 2020
- Daiichi Sankyo Sets Up Subsidiary in Vietnam
September 25, 2020
- Ohara Files Neuroblastoma Drug Dinutuximab in Japan
September 25, 2020
- LTL Pharma Looks to Acquire More Off-Patent Brands with Dellegra as a Catalyst
September 24, 2020
- Opdivo Improves PFS in 1st Line Gastric Cancer: Asian PII/III Trial
September 24, 2020
- Padcev Extends Survival in Bladder Cancer, Trial Stopped Early: Astellas/Seattle Genetics
September 24, 2020
- Sun Pharma Launches Ilumya; Its First Innovative Med in Japan
September 24, 2020
- Sumitomo Dainippon Sets Up Subsidiary in Taiwan
September 24, 2020
- Avigan Hits Primary Goal for Novel Coronavirus, Filing Eyed in October: Fujifilm
September 24, 2020
- Lenvima/Keytruda Combo Shows around 30% ORR in Triple Negative Breast Cancer, Ovarian Cancer: PII
September 24, 2020
- Keytruda’s 1st Line Gastric Cancer Submission Pulled in Japan
September 23, 2020
- 42 Nippon Chemiphar Reps to Hit Exit under Voluntary Redundancy
September 23, 2020
- Sanofi’s Dupixent Adds Pen Formulation in Japan
September 23, 2020
- Lucentis Biosimilar Filed in Japan; Senju/Gene Techno Eye 2021 Approval
September 23, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…